This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent. Top assignee: Medigene Immunotherapies Gmbh. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: Aline Bracher: Pioneering Innovations in Immunotherapy
Introduction
Aline Bracher is a notable inventor based in Munich, Germany, recognized for her significant contributions to the field of immunotherapy. With a focus on developing innovative therapeutic solutions, her work aims to enhance the efficacy of cancer treatments through the use of specific T cell receptors.
Latest Patents
Aline Bracher holds a patent for "HA-1 specific T cell receptors and their use." This impressive invention encompasses an isolated T cell receptor (TCR) that targets an allelic variant of the minor histocompatibility antigen 1 (HA-1), specifically the HA-1 allelic variant. The patent also describes an isolated polypeptide that includes a functional portion of the TCR, along with a multivalent TCR complex and related nucleic acid molecules. Furthermore, it outlines vectors, cells, antibodies, and various medical applications associated with the TCR.
Career Highlights
Currently, Aline is associated with Medigene Immunotherapies GmbH, where she plays a crucial role in advancing innovative treatments. Her work is central to the company's mission of developing cutting-edge immunotherapy solutions aimed at providing new hope for cancer patients.
Collaborations
Throughout her career, Aline has collaborated with other prominent figures in the field, including Christian Ellinger and Daniel Sommermeyer. These partnerships foster a dynamic environment that promotes the exchange of ideas and enhances the development of groundbreaking therapies.
Conclusion
Aline Bracher stands out as an influential inventor, driving progress in the field of immunotherapy through her innovative patents and collaborative efforts. Her dedication to advancing cancer treatments underscores the importance of innovation in improving patient outcomes.